GABBIANI, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 8.956
EU - Europa 3.315
AS - Asia 1.027
AF - Africa 170
SA - Sud America 16
OC - Oceania 10
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.496
Nazione #
US - Stati Uniti d'America 8.761
IT - Italia 1.377
SE - Svezia 763
CN - Cina 515
BG - Bulgaria 317
CA - Canada 193
DE - Germania 193
SG - Singapore 163
VN - Vietnam 150
UA - Ucraina 149
SN - Senegal 112
GB - Regno Unito 109
FI - Finlandia 104
TR - Turchia 97
CH - Svizzera 85
AT - Austria 66
CI - Costa d'Avorio 55
HK - Hong Kong 50
RU - Federazione Russa 41
BE - Belgio 30
IN - India 25
FR - Francia 20
GR - Grecia 14
ES - Italia 12
PL - Polonia 11
BR - Brasile 10
AU - Australia 7
IE - Irlanda 6
CZ - Repubblica Ceca 5
NL - Olanda 5
IR - Iran 4
JP - Giappone 4
NZ - Nuova Zelanda 3
PK - Pakistan 3
TW - Taiwan 3
AR - Argentina 2
IQ - Iraq 2
KR - Corea 2
LI - Liechtenstein 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BS - Bahamas 1
CL - Cile 1
CU - Cuba 1
DK - Danimarca 1
EU - Europa 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
OM - Oman 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 13.496
Città #
Woodbridge 1.615
Fairfield 1.142
Houston 930
Ann Arbor 925
Ashburn 596
Milan 530
Seattle 478
Chandler 464
Cambridge 408
Wilmington 375
Sofia 317
Serra 287
Jacksonville 252
Ottawa 183
New York 176
Beijing 174
Princeton 136
Nanjing 130
Lawrence 115
Dakar 112
Medford 112
Izmir 96
Bern 85
Jüchen 61
Abidjan 55
Dearborn 55
San Diego 52
Hong Kong 48
Des Moines 47
Dong Ket 46
Vienna 46
Rome 41
Nanchang 40
Boulder 39
Florence 33
Brussels 30
Livorno 24
Hebei 23
Pisa 23
Shenyang 22
Falls Church 21
Changsha 19
London 19
Redwood City 18
Bremen 17
Kunming 17
Pune 17
Ogden 14
Boardman 13
Hefei 13
Jiaxing 13
Norwalk 13
Tianjin 13
Padova 11
Trento 10
Fabriano 8
Prato 8
San Giuliano Terme 8
Vicopisano 8
Hangzhou 7
Auburn Hills 6
Changchun 6
Chicago 6
Giussano 6
Torino 6
Burgos 5
Edinburgh 5
Frankfurt am Main 5
Los Angeles 5
Lubin 5
Sassari 5
Wuhan 5
Council Bluffs 4
Guangzhou 4
Jinan 4
Lucca 4
Marseille 4
Noli 4
Ponte San Pietro 4
Salerno 4
Sesto Fiorentino 4
Shanghai 4
Singapore 4
Siracusa 4
São Paulo 4
Warsaw 4
Washington 4
Acton 3
Amherst 3
Atessa 3
Boydton 3
Chieti 3
Chiswick 3
Detroit 3
Dublin 3
Durham 3
Empoli 3
Graz 3
Helsinki 3
Napoli 3
Totale 10.754
Nome #
Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities 189
Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: The binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin 187
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 187
New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen 184
ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes 167
The reaction of artemisinins with hemoglobin: A unified picture 161
Gold(III) Compounds as anticancer drugs 158
Unravelling the Chemical Nature of Copper Cuprizone 155
Peculiar Mechanistic and Structural Features of the Carboplatin-Cytochrome c System Revealed by ESI MS analysis 152
X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins 151
The C2 variant of human serum transferrin retains the iron binding properties of the native protein 150
Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c 150
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation 150
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study 146
Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound 145
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme 143
PtI2(DACH), the Iodido Analogue of Oxaliplatin as a Candidate for Colorectal Cancer Treatment: Chemical and Biological Features 143
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 142
Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands 141
Antitumor gold(III) complexes 141
Arene Ruthenium Complexes with Ethacrynic Acid-Modified Ligands: Synthesis, Characterization and Antiproliferative Activity 141
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs 140
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications 138
Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds 137
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 135
Metal compounds as inhibitors of B-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer’s disease 135
Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity 135
Solution chemistry and cytotoxic properties of novel organogold(III) compounds 134
Proanthocyanidin glycosides from the leaves of Quercus ilex L. (Fagaceae) 134
The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif 134
DOTAP/DOPE and DC-Chol/DOPE Lipoplexes for Gene Delivery studied by Circular Dichroism and Biophysical Techniques 132
Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs 132
Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme 132
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study 132
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments 131
Nanoparticles of Mg(OH)2: Synthesis and Application to Paper Conservation 130
Metal-based compounds as prospective antileishmanial agents: Inhibition of Trypanothione reductase by selected gold complexes 130
Photocytotoxic Pt(iv) complexes as prospective anticancer agents 129
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis 128
Solution Behaviour and Biomolecular Interactions of Two Cytotoxic trans-Platinum(II) Complexes Bearing Aliphatic Amine Ligands 126
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound 126
Synthesis and Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic Acid-Modified Ligands 126
Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials 125
cis-Pt I2(NH3)2: a reappraisal 125
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 124
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study 123
Interaction of a Gold(I) Dicarbene Anticancer Drug with Human Telomeric DNA G-Quadruplex: Solution and Computationally Aided X-ray Diffraction Analysis 122
The copper(II) binding properties of the cyclic peptide c(HGHK) 120
The influence of auranofin, a clinically established antiarthritic gold drug, on bone metabolism: analysis of its effects on human multipotent adipose-derived stem cells, taken as a model 120
Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives 119
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 119
Structure-Function Relationships within Keppler-Type Antitumor Ruthenium(III) Complexes: the Case of 2-Aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)] 118
Anticancer gold N-Heterocyclic carbene complexes: a comparative in vitro and ex vivo study 117
Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells 117
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 114
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 114
Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action 113
Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro 113
Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(III) compounds studied with combined mass spectrometry and biochemical assays 112
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones 111
Novel platinum(II) compounds with O,S bidentate ligands: Synthesis, characterization, antiproliferative properties and biomolecular interactions 111
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles 111
Aluminum, copper, iron and zinc differentially alter amyloid-Abeta(1-42) aggregation and toxicity 110
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. 109
Interaction of gold N-heterocyclic carbenes with nucleic acids 109
Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. 109
[Au2(phen2Me)2(µ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties 107
Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex 107
New insights into the molecular mechanisms of selected anticancer metal compounds through bioinformatic analysis of proteomic data 107
New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro 107
Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. 106
Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins 106
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand 106
Reactivity and Biological Properties of a Series of Cytotoxic PtI(2)(amine)(2) Complexes, Either cis or trans Configured 106
Trans-cis-cis-[RuCl(2)(DMSO)(2)(2-amino-5-methyl-thiazole)(2)], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B 105
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds 105
Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties 105
Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents 104
The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins 103
The mode of action of anticancer gold-based drugs: A structural perspective 103
Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c 103
Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation 103
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc 101
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles 101
Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial "hot spots" for protein-protein recognition 100
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 97
Biophysical Characterization of Adducts Formed between Anticancer Metallodrugs and Selected Proteins: New Insights from X-ray Diffraction and Mass Spectrometry Studies 96
Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c 96
Proteomic analysis of the cytotoxic effects induced by the organogold(iii) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 96
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 95
Dinuclear Gold(III) Complexes as Potential Anticancer Agents: Structure, Reactivity and Biological Profile of a Series of Gold(III) Oxo-Bridged Derivatives 94
Recent progress in the application of analytical techniques to anticancer metallodrug proteomics 94
Ruthenium arene complexes with triphenylphosphane ligands: Cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution 92
Proteins as possible targets for antitumor metal complexes: biophysical studies of their interactions 90
Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability 90
Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid-beta(1-42): An AFM Study 89
Triethylphosphine gold iodide (I), the iodido analogue of Auranofin: comparative studies of a potential antineoplastic agent 89
Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for the mechanism of action 85
Protein Targets for Anticancer Gold Compounds: Mechanistic Inferences 84
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents 84
Totale 12.200
Categoria #
all - tutte 30.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.166


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019967 0 0 0 0 0 0 0 0 27 276 372 292
2019/20202.677 348 227 183 197 267 295 287 211 298 147 179 38
2020/20211.477 127 54 85 67 77 64 79 316 188 162 68 190
2021/20221.541 17 88 169 129 263 165 62 90 62 13 139 344
2022/20231.874 272 218 132 137 147 237 53 160 370 24 88 36
2023/20241.621 286 210 302 133 287 284 57 34 28 0 0 0
Totale 13.779